Viatris Stock Forecast, Price & News

-0.13 (-0.91 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.43 million shs
Average Volume10.34 million shs
Market Capitalization$17.19 billion
P/E Ratio3.33
Dividend Yield3.07%
30 days | 90 days | 365 days | Advanced Chart
Receive VTRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

Viatris logo

About Viatris

Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.68 out of 5 stars

Medical Sector

2nd out of 2,105 stocks

Pharmaceutical Preparations Industry

1st out of 832 stocks

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 3.8 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Viatris (NASDAQ:VTRS) Frequently Asked Questions

Is Viatris a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last year. There are currently 1 sell rating, 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Viatris stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTRS, but not buy additional shares or sell existing shares.
View analyst ratings for Viatris
or view top-rated stocks.

What stocks does MarketBeat like better than Viatris?

Wall Street analysts have given Viatris a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viatris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Viatris?

Viatris saw a decline in short interest in May. As of May 28th, there was short interest totaling 20,620,000 shares, a decline of 38.7% from the May 13th total of 33,650,000 shares. Based on an average daily volume of 9,320,000 shares, the days-to-cover ratio is presently 2.2 days.
View Viatris' Short Interest

When is Viatris' next earnings date?

Viatris is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Viatris

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) announced its quarterly earnings results on Monday, May, 10th. The company reported $0.92 EPS for the quarter, topping the Zacks' consensus estimate of $0.80 by $0.12. The company earned $4.43 billion during the quarter, compared to analyst estimates of $4.19 billion. Viatris had a positive trailing twelve-month return on equity of 8.47% and a negative net margin of 12.56%. Viatris's revenue for the quarter was up 69.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.90 EPS.
View Viatris' earnings history

How often does Viatris pay dividends? What is the dividend yield for Viatris?

Viatris announced a quarterly dividend on Monday, May 10th. Shareholders of record on Monday, May 24th will be paid a dividend of $0.11 per share on Wednesday, June 16th. This represents a $0.44 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Friday, May 21st.
View Viatris' dividend history

Is Viatris a good dividend stock?

Viatris pays an annual dividend of $0.44 per share and currently has a dividend yield of 3.07%.
View Viatris' dividend history.

What guidance has Viatris issued on next quarter's earnings?

Viatris updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $17.20 billion-17.80 billion, compared to the consensus revenue estimate of $17.50 billion.

What price target have analysts set for VTRS?

15 analysts have issued 1 year target prices for Viatris' stock. Their forecasts range from $15.00 to $24.00. On average, they expect Viatris' share price to reach $18.20 in the next year. This suggests a possible upside of 28.0% from the stock's current price.
View analysts' price targets for Viatris
or view top-rated stocks among Wall Street analysts.

Who are Viatris' key executives?

Viatris' management team includes the following people:
  • Mr. Robert J. Coury, Exec. Chairman (Age 60, Pay $16.61M)
  • Mr. Michael Goettler, CEO & Exec. Director (Age 53, Pay $3.07M)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 60, Pay $6.87M)
  • Mr. Sanjeev Narula, Chief Financial Officer (Age 60, Pay $2.5M)
  • Mr. Anthony Mauro, Pres of Developed Markets (Age 48, Pay $3.54M)
  • Mr. Sanjeev Kumar Sethi, Chief Operating Officer (Age 54)
  • Mr. Paul B. Campbell, Chief Accounting Officer, Sr. VP & Corp. Controller (Age 54)
  • Mr. Ramkumar Rayapureddy, Chief Information Officer
  • Ms. Melissa Trombetta, Head of Global Investor Relations
  • Mr. Brian S. Roman, Global Gen. Counsel (Age 51)

What is Michael Goettler's approval rating as Viatris' CEO?

8 employees have rated Viatris CEO Michael Goettler on Michael Goettler has an approval rating of 85% among Viatris' employees.

Who are some of Viatris' key competitors?

What is Viatris' stock symbol?

Viatris trades on the NASDAQ under the ticker symbol "VTRS."

Who are Viatris' major shareholders?

Viatris' stock is owned by many different institutional and retail investors. Top institutional investors include Schroder Investment Management Group (0.12%), Perceptive Advisors LLC (0.08%), Advisor Partners LLC (0.01%), HM Payson & Co. (0.00%), Advisory Services Network LLC (0.00%) and Lehman & Derafelo Financial Resources LLC (0.00%). Company insiders that own Viatris stock include James M Kilts and W Don Cornwell.
View institutional ownership trends for Viatris

Which major investors are selling Viatris stock?

VTRS stock was sold by a variety of institutional investors in the last quarter, including Lehman & Derafelo Financial Resources LLC.
View insider buying and selling activity for Viatris
or view top insider-selling stocks.

Which major investors are buying Viatris stock?

VTRS stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Perceptive Advisors LLC, Advisor Partners LLC, HM Payson & Co., Advisory Services Network LLC, Sunbelt Securities Inc., Pathway Financial Advisors LLC, and Rehmann Capital Advisory Group. Company insiders that have bought Viatris stock in the last two years include James M Kilts, and W Don Cornwell.
View insider buying and selling activity for Viatris
or or view top insider-buying stocks.

How do I buy shares of Viatris?

Shares of VTRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viatris' stock price today?

One share of VTRS stock can currently be purchased for approximately $14.22.

How much money does Viatris make?

Viatris has a market capitalization of $17.19 billion and generates $11.95 billion in revenue each year.

How many employees does Viatris have?

Viatris employs 45,000 workers across the globe.

What is Viatris' official website?

The official website for Viatris is

Where are Viatris' headquarters?

Viatris is headquartered at 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317.

How can I contact Viatris?

Viatris' mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at (724) 514-1800 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.